Last edited by Gacage
Wednesday, July 29, 2020 | History

1 edition of Hormones, receptors, and breast cancer found in the catalog.

Hormones, receptors, and breast cancer

Hormones, receptors, and breast cancer

  • 233 Want to read
  • 38 Currently reading

Published by Raven Press in New York .
Written in English

    Subjects:
  • Breast -- Cancer -- Endocrine aspects.,
  • Hormone receptors.,
  • Steroid hormones -- Therapeutic use.,
  • Receptors, Hormone -- Metabolism -- Congresses.,
  • Receptors, Estrogen -- Metabolism -- Congresses.,
  • Breast neoplasms -- Metabolism -- Congresses.

  • Edition Notes

    Statementedited by William L. McGuire.
    SeriesProgress in cancer research and therapy ;, v. 10
    ContributionsMcGuire, William L., United States-Japan Cooperative Research Program.
    Classifications
    LC ClassificationsRC280.B8 H663
    The Physical Object
    Paginationxiii, 369 p. :
    Number of Pages369
    ID Numbers
    Open LibraryOL4570936M
    ISBN 100890042616
    LC Control Number77090595

      -Cancer causation, metabolism, and hormone-dependence-Disease progression, prevention, treatment, and resistance-Translational studies dealing with novel therapeutic agents-Hormone receptors and their co-regulatory molecules-Hormonally influenced signaling pathways-Nuclear and steroid hormone receptors-Adrenal, pituitary, and thyroid hormones. Hormone treatments lower the levels of oestrogen or progesterone in the body, or block their effects. Hormone therapy is only likely to work if the breast cancer cells have oestrogen receptors (ER). Your doctor checks your cancer cells for these receptors when you are diagnosed. Around 7 out of 10 breast cancers (70%) have oestrogen receptors.

    Hormone Receptor-Positive Breast Cancer. About 80% of all breast cancers are “ER-positive.” That means the cancer cells grow in response to the hormone estrogen. About 65% of these are also. Hormone receptor positive breast cancer has both estrogen receptor positive (ER+) and progesterone receptor positive (PR+) tumor receptor status. Up to two-thirds of invasive breast cancers are classified as hormone receptor positive, or ER+/PR+. These cancers are .

      Breast cancer is the most common malignant disease and leading cause of cancer-related death for women worldwide. Among all subtypes, estrogen receptor-positive (ER +, i.e. expressing estrogen receptors endogenously) breast cancer is the most prevalent type, accounting for approximately 75% of all clinical situations, hormone therapy targeting the estrogen (ER) Cited by: 1. Endocrine therapies are widely used in the treatment of recurrent/metastatic estrogen receptor–positive (ER+) advanced breast cancer, given their proven efficacy and generally favorable side-effect profile. 1 Unfortunately, not all patients respond to first-line endocrine treatment due to primary de novo resistance, while others may initially respond but eventually progress with secondary.


Share this book
You might also like
case of Gresham college, relating to the lectures there

case of Gresham college, relating to the lectures there

illustrated history of the naval stores (turpentine) industry

illustrated history of the naval stores (turpentine) industry

Thermodynamic Values at Low Temperature for Natural Inorganic Materials

Thermodynamic Values at Low Temperature for Natural Inorganic Materials

Gunners instruction

Gunners instruction

early start

early start

introduction to chemisorption and catalysis by metals

introduction to chemisorption and catalysis by metals

Walled city

Walled city

Reclaiming paradise

Reclaiming paradise

Tacita Dean.

Tacita Dean.

Fiction of the Forties

Fiction of the Forties

abridged catalogue of REAL lighting equipment.

abridged catalogue of REAL lighting equipment.

construction of personality

construction of personality

The Illustrated Bhagavad Gita

The Illustrated Bhagavad Gita

Hormones, receptors, and breast cancer Download PDF EPUB FB2

"Hormones play an essential role in both the development of breast cancer and its therapy. This text provides a comprehensive review of the key receptors and signaling pathways that effect breast cancer growth leading figures in the field provide insight into the basic biology and clinical issues relevant to this devastating disease."Manufacturer: Springer.

Hormone Receptors in Breast Cancer (Cancer Treatment and Research): Medicine & Health Science Books @ This book provides an up-to-date resource of the role of hormone receptors in breast cancer written in depth for both the basic molecular academic researcher and translational scientist.

Advances in basic science of molecular endocrinology have undoubtedly been translated into clinical practice, and clinicians caring for this disease need to be. Genre/Form: Congress Konferenzschrift: Additional Physical Format: Online version: Hormones, receptors, and breast cancer.

New York: Raven Press, ©   Hormones and Breast Cancer Elsevier, - Medical - pages 0 Reviews First published inVitamins and Hormones is the. Purchase Hormones and Breast Cancer, Volume 93 - 1st Edition.

Print Book & E-Book. ISBNOn the other hand, other steroid receptors, such as vitamin D receptor, glucocorticoid and androgen receptors (11, 12), as well as tyrosine kinase receptors, including IGF-1 and insulin receptors (13–15), can be also expressed in breast cells, and their roles and significance in cancer cell growth might deserve further investigation.

They encompass estrogen receptor (ERα), progesterone receptor (PR), androgen receptor and breast cancer book, and estrogen receptor β (ER β). PR receptors exist in two isoforms, namely, PRA and PRB. The levels are equally distributed in normal breast, but during carcinogenesis there is often an imbalance (toward increase in PRA).

Most breast cancers -- about 70% -- are sensitive to the hormones estrogen or progesterone. These tumors have a sort of biological on-off switch called a hormone receptor. Estrogen and progesterone Author: Annie Stuart. Receptors are proteins in or on cells that can attach to certain substances in the blood.

Normal breast cells and some breast cancer cells have receptors that attach to the hormones estrogen and progesterone, and depend on these hormones to grow. Breast cancer cells may have one, both, or none of these receptors. Numerous studies using cultured cells, as well as human breast cancer tissue, have demonstrated the presence of receptors for several of these hormones in human breast cancer cells.

Genetic aberrations in growth factor signaling pathways, for the most part acquired, are inextricably linked to developmental abnormalities and to a variety of. The 11 chapters of this book examine many aspects of hormone receptors, including basic and translational information on the molecular biology of the ERs, the utility of the ERs for the clinical management of breast cancer as it relates to assessing clinical outcome and selecting appropriate therapy, a review on the biology of ER and its role.

Hormone Receptors in Breast Cancer provides an up-to-date resource of the role of hormone receptors in breast cancer written in depth for. The breast cancer cells have receptors (proteins) that attach to estrogen and progesterone, which helps them grow.

Treatments that stop these hormones from attaching to these receptors are called hormone or endocrine therapy. Hormone therapy can reach cancer cells almost anywhere in the body and not just in the breast. Hormone Receptors in Breast Cancer provides an up-to-date resource of the role of hormone receptors in breast cancer written in depth for both the basic.

Normal breast cells and some breast cancer cells contain receptors that attach to estrogen and progesterone. These 2 hormones often fuel the growth of breast cancer cells.

An important step in evaluating a breast cancer is to test the cancer removed during the biopsy (or surgery) to see if it has estrogen and progesterone receptors.

If the breast cancer recurs in the future as advanced disease, doctors should order a repeat biopsy and retest the cancer for hormone receptors. If the cancer cells no longer have receptors, hormonal therapy is unlikely to help treat the cancer. If the cells have gained hormone receptors, however, then hormonal therapy may be helpful.

Hormone Receptors in Breast Cancer PDF Author Suzanne A. Fuqua Isbn File size MB Year Pages Language English File format PDF Category Free Medical Books,Oncology Download the Book Download Book Description: Hormone Receptors in Breast Cancer provides an up-to-date resource of the role of hormone receptors in breast cancer written.

Hormone status of breast cancers includes: Estrogen receptor (ER) positive. The cells of this type of breast cancer have receptors that allow them to use the hormone estrogen to grow.

Treatment with anti-estrogen hormone (endocrine) therapy can block the growth of the cancer cells. Progesterone receptor (PR) positive. Sex hormones play a central role in the development of breast cancer.

Sex hormone–binding globulin (SHBG) modulates the bioavailability of circulating sex hormones and regulates their signaling system in the breast tissue.

We evaluated the association of a common functional polymorphism (AspAsn) in the SHBG gene with breast cancer risk in a population-based case-control study (1. Hormone receptors play a key role in regulating the growth and differentiation of breast epithelium and hormone receptor status is a prognostic indicator in invasive carcinoma.

The expression of hormone receptors as determined by immunohistochemical stains indicates that the cells retain the ability to be manipulated by exogenous hormone therapy. Research indicates that nearly two-thirds of invasive breast cancer is classified as hormone receptor positive, so it’s a really great question to ask.

The quality of your diet and nutrition while going through breast cancer can play a pivotol role, not only for getting well, but also for staying well and avoiding recurrences.Yes.

Most breast cancers are ER positive, and clinical trials have tested whether hormone therapy can be used to prevent breast cancer in women who are at increased risk of developing the disease.

A large NCI-sponsored randomized clinical trial called the Breast Cancer Prevention Trial found that tamoxifen, taken for 5 years, reduced the risk of developing invasive breast cancer by about 50%.